

Dr. med. Eva Ebnöther

AML, MDS und ALL

Bibliografie

- ¹ Wei AH, et al.: Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. *Blood* 2020 Jun 11; 135(24): 2137–2145.
- ² DiNardo C, et al.: A randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-naïve patients with acute myeloid leukemia ineligible for intensive therapy. Presented at EHA 2020, LBA 2601.

- ³ Platzbecker U, et al.: Treatment with imetelstat provides durable transfusion independence in heavily transfused non-DEL(5Q) lower risk MDS relapsed/refractory to erythropoiesis stimulating agents. Presented at EHA 2020, S183.
- ⁴ Peters C, et al.: TBI or chemotherapy based conditioning for children and adolescents with ALL: a prospective randomized multicenter study «FORUM» on behalf of the AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP. Presented at EHA 2020, S102.